New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
14:25 EDTQGEN, QGEN, NSPH, NSPH, ILMN, ILMN, HOLX, HOLX, BRKR, BRKR, BDX, BDX, ABT, ABT, TMO, TMOLeerink analyst/industry conference call on June 26 is now 2 pm
Life Science Tools & Diagnostics Analyst Leonard discusses trends and controversies in molecular diagnostics on an Analyst/Industry conference call. Relevant companies ABT, BDX, BRKR, HOLX, ILMN, NSPH, QGEN and TMO may be included on the Analyst/Industry conference call to be held on June 26 at 2 pm.
News For QGEN;NSPH;ILMN;HOLX;BRKR;BDX;ABT;TMO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 22, 2015
07:44 EDTILMNIllumina price target lowered to $250 from $275 at Canaccord
Subscribe for More Information
06:05 EDTTMOThermo Fisher reports Q2 Life Sciences Solutions revenue $1.13B
Subscribe for More Information
06:04 EDTTMOThermo Fisher reports Q2 organic revenue growth of 6%
Subscribe for More Information
06:03 EDTTMOThermo Fisher raises FY15 adjusted EPS to $7.28-$7.41-$7.25-$7.40
Subscribe for More Information
06:02 EDTTMOThermo Fisher reports Q2 EPS $1.84, consensus $1.78
Subscribe for More Information
05:45 EDTILMNIllumina should be bought on post-earnings selloff, says Mizuho
Subscribe for More Information
July 21, 2015
19:00 EDTILMNOn The Fly: After Hours Movers
Subscribe for More Information
16:24 EDTILMNIllumina drops sharply after results
Subscribe for More Information
16:16 EDTILMNIllumina reports Q2 cash flow from operations of $171M, free cash flow $130M
16:15 EDTILMNIllumina reports Q2 gross margin 69.8% vs. 67.1% a year ago
16:15 EDTILMNIllumina raises FY15 adjusted EPS view to $3.39-$3.45 from $3.36-$3.42
Subscribe for More Information
16:13 EDTILMNIllumina reports Q2 adjusted EPS 80c, consensus 77c
Subscribe for More Information
15:02 EDTTMO, ABTNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Coca-Cola (KO), consensus 60c... Boeing (BA), consensus $1.42... Abbott Laboratories (ABT), consensus 50c... Thermo Fisher Scientific (TMO), consensus $1.78... EMC (EMC), consensus 41c... Illinois Tool Works (ITW), consensus $1.28... St. Jude Medical (STJ), consensus $1.00... Northern Trust (NTRS), consensus 96c... Check Point Software (CHKP), consensus 95c... Polaris Industries (PII), consensus $1.58... Interpublic Group (IPG), consensus 27c... New York Community Bancorp (NYCB), consensus 26c... B/E Aerospace (BEAV), consensus 76c... Owens Corning (OC), consensus 54c... Knight Transportation (KNX), consensus 37c.
15:02 EDTILMNNotable companies reporting after market close
Subscribe for More Information
July 20, 2015
09:02 EDTABTAbbott receives FDA approval and launches iDesign Advanced WaveScan system
Subscribe for More Information
08:38 EDTABTAnalyst predicts Zoetis merges with Bayer unit, not Valeant
Zoetis (ZTS) in recent months has been the subject of takeover speculation, possibly for Valeant (VRX), but a Jefferies analyst told investors today in a research note that he views a deal with a unit of healthcare giant Bayer (BAYRY) as "highly likely" for the animal medicine company. BACKGROUND: Bill Ackman of Pershing Square, who owns stakes in both Zoetis and Valeant, said in early May while speaking on CNBC that Zoetis is a "great” business on a standalone basis, but he also spoke of the company's strategic value. Ackman added, however, that he was "not sure" that Valeant was the best acquirer of Zoetis. Subsequently, in late June, The Wall Street Journal reported that Valeant made a preliminary approach regarding a potential deal to buy Zoetis. CNBC's David Faber said the next day, citing his own sources, that Valeant reached out to Zoetis as a courtesy to common shareholder Ackman and was unlikely to pursue an acquisition of the company, though he cautioned then Valeant could change its approach and pursue a deal. BAYER: Jefferies analyst Jeffrey Holford said in a note today that he views a tie-up between Zoetis and Bayer's Animal Health business in 2016 as "highly likely." He sees Mylan's (MYL) acquisition of Abbott's (ABT) non‑U.S. developed markets specialty and branded generics business as a potential proxy for how a transaction could be structured, adding that such a "spinversion" could achieve up to 36% long-term earnings accretion for Zoetis. Holford reiterated a Buy rating on Zoetis with a $60 price target, while downgrading Bayer to Hold, citing valuation following the recent outperformance of its shares. IDEXX: While being discussed as a target, some analysts have also opined on companies that Zoetis could pursue as a buyer. On June 29, Canaccord said that in investor meetings with IDEXX (IDXX) executives declined to comment on Zoetis' potential interest in scaling up its animal health diagnostics business. Canaccord added that it thought Zoetis could make a bid for IDEXX. The firm reiterated its Buy rating and $80 price target on IDEXX shares at that time. PRICE ACTION: Since June 25, the day the Journal first reported on Valeant's preliminary takeover approach to Zoetis, the animal health company's shares have dropped nearly 4%. Zoetis closed down 20c to $47.80 on Friday.
07:33 EDTABT, HOLXInternational AIDS Society to hold a conference
Subscribe for More Information
07:32 EDTBRKRAlzheimer's Association to hold a conference
Subscribe for More Information
07:30 EDTABTZoetis 'highly likely' to merge with Bayer unit in 2016, says Jefferies
Subscribe for More Information
06:17 EDTILMN, TMOMizuho sees Q2 earnings beats in Diagnostics space
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use